• Home
  • About Us
  • Platform
  • Pipeline
  • key executives
  • Advisors
  • Collaborations
  • Press Releases
  • Contact
  • More
    • Home
    • About Us
    • Platform
    • Pipeline
    • key executives
    • Advisors
    • Collaborations
    • Press Releases
    • Contact
  • Home
  • About Us
  • Platform
  • Pipeline
  • key executives
  • Advisors
  • Collaborations
  • Press Releases
  • Contact

Development Programs

Antliabio110 - A novel long-acting subcutaneous peptide-based therapy for the treatment of treatment resistant hypertension (rHTN)


  • Status - IND enabling


Antliabio 111 - A novel long-acting peptide-based therapy for the treatment of pulmonary arterial hypertension


  • Status - Preclinical Development


Antliabio 112 - A novel long-acting peptide-based therapy for the treatment of chronic heart failure (HFpEF and HFrEF)


  • Status - Preclinical Development


Antliabio 113 - A novel long-acting peptide-based therapy for the treatment of severe asthma


  • Status - Preclinical Development


Antliabio210 - A novel long-acting peptide-based therapy for the treatment of multiple cardiovascular, pulmonary, and metabolic diseases


  • Status - Preclinical Development


Antliabio310 - A novel long-acting peptide-based therapy for the treatment of cardiovascular diseases


  • Status - Preclinical Development



Copyright © 2023 Antlia Bioscience, Inc. - All Rights Reserved.

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept